



**HAL**  
open science

## **HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond**

Carla Marini, Alessandro Porro, Agnès Rastetter, Carine Dalle, Ilaria Rivolta, Daniel Bauer, Renske Oegema, Caroline Nava, Elena Parrini, Davide Mei, et al.

### ► **To cite this version:**

Carla Marini, Alessandro Porro, Agnès Rastetter, Carine Dalle, Ilaria Rivolta, et al.. HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond. *Brain - A Journal of Neurology*, 2018, 141 (11), pp.3160-3178. <10.1093/brain/awy263>. <hal-01977974>

**HAL Id: hal-01977974**

**<https://hal.sorbonne-universite.fr/hal-01977974v1>**

Submitted on 11 Jan 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

***HCNI* mutation spectrum: from neonatal epileptic encephalopathy to benign  
generalized epilepsy and beyond**

Carla Marini<sup>1,43\*#</sup>, Alessandro Porro<sup>2\*</sup>, Agnès Rastetter<sup>3\*</sup>, Carine Dalle<sup>3\*</sup>, Ilaria Rivolta<sup>4</sup>, Daniel Bauer<sup>5</sup>, Renske Oegema<sup>6</sup>, Caroline Nava<sup>3,7,43</sup>, Elena Parrini<sup>1</sup>, Davide Mei<sup>1</sup>, Catherine Mercer<sup>8</sup>, Radhika Dhamija<sup>9</sup>, Chelsea Chambers<sup>10</sup>, Christine Coubes<sup>11</sup>, Julien Thévenon<sup>12</sup>, Paul Kuentz<sup>12,13</sup>, Sophie Julia<sup>14</sup>, Laurent Pasquier<sup>15</sup>, Christèle Dubourg<sup>16</sup>, Wilfrid Carré<sup>16</sup>, Anna Rosati<sup>1</sup>, Federico Melani<sup>1</sup>, Tiziana Pisano<sup>1</sup>, Maria Giardino<sup>1</sup>, A. Micheil Innes<sup>17</sup>, Yves Alembik<sup>18</sup>, Sophie Scheidecker<sup>18</sup>, Manuela Santos<sup>19</sup>, Sonia Figueiroa<sup>19</sup>, Cristina Garrido<sup>19</sup>, Carlo Fusco<sup>20</sup>, Daniele Frattini<sup>20</sup>, Carlotta Spagnoli<sup>20</sup>, Anna Binda<sup>4</sup>, Tiziana Granata<sup>21</sup>, Francesca Ragona<sup>21</sup>, Elena Freri<sup>21</sup>, Silvana Franceschetti<sup>21</sup>, Laura Canafoglia<sup>21</sup>, Barbara Castellotti<sup>21</sup>, Cinzia Gellera<sup>21</sup>, Raffaella Milanese<sup>22</sup>, Maria Margherita Mancardi<sup>23</sup>, Damien R. Clark<sup>24</sup>, Fernando Kok<sup>25</sup>, Katherine L. Helbig<sup>26</sup>, Shoji Ichikawa<sup>27</sup>, Laurie Sadler<sup>28</sup>, Jana Neupauerová<sup>29</sup>, Petra Laššuthova<sup>29</sup>, Katalin Štěrbová<sup>29,43</sup>, Annick Laridon<sup>30</sup>, Eva Brilstra<sup>6,43</sup>, Bobby Koeleman<sup>6,43</sup>, Johannes R. Lemke<sup>31,43</sup>, Federico Zara<sup>32</sup>, Pasquale Striano<sup>33,43</sup>, Julie<sup>34</sup>Soblet<sup>35,36</sup>, Guillaume<sup>34</sup>Smits<sup>35,36</sup>, Nicolas Deconinck<sup>37</sup>, Andrea Barbuti<sup>22</sup>, Dario DiFrancesco<sup>22</sup>, Eric LeGuern<sup>3,7,43</sup>, Renzo Guerrini<sup>1,43</sup>, Bina Santoro<sup>38</sup>, Kay Hamacher<sup>5</sup>, Gerhard Thiel<sup>39</sup>, Anna Moroni<sup>2</sup>, Jacopo C. DiFrancesco<sup>21,40</sup>, Christel Depienne<sup>3,41,42,43#</sup>

## **AFFILIATIONS**

- <sup>1</sup> Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Neuroscience Department, A. Meyer Children's Hospital, University of Florence, Viale Pieraccini 24, 50139, Florence, Italy.
- <sup>2</sup> Department of Biosciences, University of Milan, 20133 Milan, Italy.
- <sup>3</sup> Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France.
- <sup>4</sup> School of Medicine and Surgery, University Milano-Bicocca, Monza, Italy.
- <sup>5</sup> Computational Biology & Simulation Group, Department of Biology, Technische Universität Darmstadt, 64287 Darmstadt, Germany.
- <sup>6</sup> Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
- <sup>7</sup> AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique, 75013, Paris, France.
- <sup>8</sup> Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
- <sup>9</sup> Department of Clinical Genomics and Neurology, Mayo Clinic, Phoenix, AZ, USA.
- <sup>10</sup> Department of Neurosciences, University of Virginia, Charlottesville, VA, 22908, USA.
- <sup>11</sup> Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, Montpellier, France.
- <sup>12</sup> FHU-TRANSLAD, Université de Bourgogne/CHU Dijon and INSERM UMR 1231 GAD team, Genetics of Developmental Anomalies, Université de Bourgogne-Franche Comté, Dijon, France.
- <sup>13</sup> Génétique Biologique Histologie, CHRU de Besançon, Besançon, France.
- <sup>14</sup> Service de génétique médicale, Pôle de biologie, CHU de Toulouse - Hôpital Purpan,

Toulouse, France.

<sup>15</sup> Service de Génétique Clinique, Centre Référence « Déficiences Intellectuelles de causes rares » (CRDI), CHU Rennes, 35203 Rennes, France.

<sup>16</sup> Laboratoire de Génétique Moléculaire & Génomique, CHU de Rennes, 35033 Rennes, France.

<sup>17</sup> Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

<sup>18</sup> Laboratoires de génétique, Institut de génétique médicale d'Alsace, Hôpitaux Universitaires de Strasbourg, 67 000 Strasbourg, France.

<sup>19</sup> Neuropediatric Department, Centro Hospitalar do Porto, Porto Portugal.

<sup>20</sup> Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy.

<sup>21</sup> Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

<sup>22</sup> Department of Biosciences, The PaceLab, Università degli Studi di Milano, Milan, Italy.

<sup>23</sup> Child Neuropsychiatry Unit, Department of Medical and Surgical Neurosciences and Rehabilitation, IRCCS Istituto Giannina Gaslini, Genova, Italy.

<sup>24</sup> Women's and Children's Hospital, Adelaide, Australia.

<sup>25</sup> Mendelics Genomic Analysis, Sao Paulo, SP, Brazil.

<sup>26</sup> Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

<sup>27</sup> Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, CA, USA.

<sup>28</sup> Division of Genetics, Department of Pediatrics, Oishei Children's Hospital, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, State University of New York, Buffalo, NY, 14203, USA.

- <sup>29</sup> Department of Child Neurology, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- <sup>30</sup> Department of Neurology, Academic Center for Epileptology, Kempenhaeghe/Maastricht University Medical Center, Heeze, The Netherlands.
- <sup>31</sup> Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.
- <sup>32</sup> Laboratory of Neurogenetics and Neuroscience, Institute G. Gaslini, Genova, Italy.
- <sup>33</sup> Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, "G. Gaslini" Institute, Genova, Italy.
- <sup>34</sup> Department of Genetics, Hôpital Universitaire des Enfants Reine Fabiola, ULB Center of Human Genetics, Université Libre de Bruxelles, Brussels, Belgium.
- <sup>35</sup> Department of Genetics, Hôpital Erasme. ULB Center of Human Genetics, Université Libre de Bruxelles, Brussels, Belgium.
- <sup>36</sup> Interuniversity Institute of Bioinformatics in Brussels, Université Libre de Bruxelles, Brussels, Belgium.
- <sup>37</sup> Department of Pediatric Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, ULB, Brussels, Belgium.
- <sup>38</sup> Department of Neuroscience, Columbia University, New York, NY 10032, USA.
- <sup>39</sup> Membrane Biophysics, Department of Biology, Technische Universität Darmstadt, 64287 Darmstadt, Germany.
- <sup>40</sup> Department of Neurology, San Gerardo Hospital, University Milano-Bicocca, Monza, Italy.

<sup>41</sup> IGBMC, CNRS UMR 7104/INSERM U964/Université de Strasbourg, 67400 Illkirch, France.

<sup>42</sup> Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

<sup>43</sup> EuroEPINOMICS RES consortium.

\* Co-first authors

#to whom correspondence should be addressed:

Christel Depienne, Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany. Email:

[christel.depienne@uni-due.de](mailto:christel.depienne@uni-due.de)

or

Carla Marini, Pediatric Neurology Unit, A. Meyer Children's Hospital, University of Florence, Viale Pieraccini 24, 50139, Florence, Italy. Email: [carla.marini@meyer.it](mailto:carla.marini@meyer.it)

## ABSTRACT

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels control neuronal excitability and their dysfunction has been linked to epileptogenesis but very few individuals with neurological disorders related to variants altering HCN channels have been reported so far. In 2014, we described five individuals with epileptic encephalopathy due to *de novo HCN1* variants.

To further delineate *HCN1*-related disorders and investigate genotype-phenotype correlations, we assembled a cohort of 33 unpublished patients with novel pathogenic or likely pathogenic variants: 19 probands carrying 14 different *de novo* mutations and 4 families with dominantly-inherited variants segregating with epilepsy in 14 individuals, but not penetrant in six additional individuals. Sporadic patients had epilepsy with median onset at age 7 months and in 36% the first seizure occurred during a febrile illness. Overall, considering familial and sporadic patients, the predominant phenotypes were mild, including genetic generalized epilepsies and genetic epilepsy with febrile seizures plus (GEFS+) spectrum. About 20% manifested neonatal/infantile onset otherwise unclassified epileptic encephalopathy. The study also included eight patients with variants of unknown significance: one adopted patient had two *HCN1* variants, four probands had intellectual disability without seizures, and three individuals had missense variants inherited from an asymptomatic parent. Of the 18 novel pathogenic missense variants identified, 12 were associated with severe phenotypes and clustered within or close to transmembrane domains, while variants segregating with milder phenotypes were located outside transmembrane domains, in the intracellular N- and C-terminal parts of the channel. Five recurrent variants were associated with similar phenotypes. Using whole-cell patch-clamp,

we showed that the impact of 12 selected variants ranged from complete loss-of-function to significant shifts in activation kinetics and/or voltage dependence. Functional analysis of three different substitutions altering Glycine 391 revealed that these variants had different consequences on channel biophysical properties. The Gly391Asp variant, associated with the most severe, neonatal phenotype, also had the most severe impact on channel function. Molecular dynamics simulation on channel structure showed that homotetramers were not conducting ions because the permeation path was blocked by cation(s) strongly complexed to the aspartate residue, while heterotetramers showed an instantaneous current component possibly linked to deformation of the channel pore. In conclusion, our results considerably expand the clinical spectrum related to *HCNI* variants to include common generalized epilepsy phenotypes and further illustrate how *HCNI* has a pivotal function in brain development and control of neuronal excitability.

## Introduction

Hyperpolarization-activated, Cyclic Nucleotide-gated (HCN) channels constitute a unique class of voltage-gated ion channels comprising four different paralogous subtypes encoded by different genes (*HCN1-4*) in human (Ludwig *et al.*, 1998; Santoro *et al.*, 1998). Composed of four homomeric or heteromeric subunits, HCN channels are permeable to potassium and, to a lesser extent, to sodium. HCN channels are activated upon hyperpolarization, remain open at negative voltages and their opening is potentiated by binding of cAMP (Biel *et al.*, 2009). They conduct an inward, depolarizing current named  $I_f$  (“funny” current) in the heart and  $I_h$  (“hyperpolarization-activated” current) in the brain (Postea and Biel, 2011; DiFrancesco and DiFrancesco, 2015). The generation of this depolarizing current drives the membrane potential back toward the threshold for calcium and sodium channel activation, thereby allowing action potential firing.

In the brain, HCN channels are involved in multiple regulatory functions including the stabilization of resting membrane potential, the integration of synaptic inputs, the modulation of rhythmic oscillatory activity in individual neurons and neuronal networks and they are therefore essential for the control of neuronal excitability (Poolos *et al.*, 2002; Poolos, 2012; Benarroch, 2013). All four HCN subtypes are expressed in the mammalian brain but their expression greatly varies from one brain region to the other, HCN1 being the predominant isoform expressed in the cortex (Moosmang *et al.*, 1999; Monteggia *et al.*, 2000). Furthermore, HCN subtypes have distinct electrophysiological properties, HCN1 showing the most positive threshold for activation, the fastest activation kinetics, and the lowest sensitivity to cAMP (Chen *et al.*, 2001).

Increasing evidence over the last decade indicated that long-term deregulation of  $I_h$  current

properties, due to abnormal HCN channel expression or cellular distribution, are early and probably key events of epileptogenic processes in rodent models with acquired seizures (Noam *et al.*, 2011). Interestingly, both the upregulation and downregulation of HCN channels have been associated with epileptic activity in different animal models (Noam *et al.*, 2011). An increase of HCN1 channels has also been observed in brain tissue of patients with temporal lobe epilepsy after exeresis (Bender *et al.*, 2003). In 2014, we reported that *de novo HCN1* missense variants cause an early infantile epileptic encephalopathy (EIEE) sharing common features with Dravet syndrome (Nava *et al.*, 2014a).

Herein, we report on clinical, electrophysiological, genetic and functional data of novel patients with *de novo* or inherited *HCNI* variants. The cohort includes sporadic and familial patients in whom analysis of clinical manifestations uncovered a large spectrum of phenotypes ranging from the very mild and benign febrile seizures (FS), febrile seizures plus (FS+), and genetic generalized epilepsy (GGE) to moderately severe forms of genetic generalized epilepsy with febrile seizure plus (GEFS+), focal or unclassified epilepsy and to catastrophic neonatal or infantile epileptic encephalopathy. Interestingly, the cohort further includes four patients with intellectual disability (ID) and autism spectrum disorder (ASD) without seizures. We also characterized the biophysical properties of mutant channels for 12 out of the 18 novel variants identified, and investigated possible genotype-phenotype correlations.

## Material and methods

### Patients

We collected electroclinical and genetic data of 19 patients carrying *de novo* variants in the *HCNI* gene from highly heterogeneous cohorts of patients with paediatric epilepsies, either refractory or benign and with a supposed genetic aetiology. In addition, we studied four families in which *HCNI* variants segregated with epilepsy in at least two affected members. Patients and families were recruited from epilepsy and genetic centres around Europe (Italy, France, Netherlands, Germany, United Kingdom, Czech Republic, Portugal, Switzerland and Belgium), Brazil, USA, Canada and Australia. Patients 11 and 36 were recruited through Decipher (ID: 260229 and 357848) (Firth *et al.*, 2009). Collection and analysis of retrospective clinical, EEG, neuropsychological and neuroimaging data were assessed using a specific format filled by the treating specialist aiming to obtain accurate and homogenous information. We classified seizure types and epilepsy/syndromes according the ILAE guidelines (Fisher *et al.*, 2014). We also included eight patients with variants altering *HCNI* but classified as variants of unknown significance (VUS) based on unusual inheritance or phenotype: two patients with ID but no epilepsy carrying *de novo* *HCNI* variants, two patients with ID or ASD with a heterozygous deletion encompassing exon 4 of *HCNI* identified by microarrays, an adopted child with two heterozygous *HCNI* variants, and three probands with *HCNI* missense variants inherited from healthy parents. Patient 37 was briefly previously reported (Nava *et al.*, 2014a; Nava *et al.*, 2014b); all other patients are novel.

### Genetic studies

Genetic studies were independently performed in diagnostic or research laboratories using next generation sequencing. Details on the methods used to detect the *HCNI* variants in each patient are indicated in Supplementary Table 1. Sanger traces confirming variant existence were collected for 25/29 index patients. Sanger sequencing was not performed in patient 3 for whom variant accuracy was supported by a high sequencing depth (>850X). For the remaining three patients (patients 10, 13 and 41), we obtained the written report of the genetic tests performed by private laboratories but could not directly access to sequence data. Variants identified in patients 2 and 12 were previously reported (Parrini et al., 2017). The ACMG criteria and the Intervar interface (<http://wintervar.wglab.org/>) were used to filter and classify *HCNI* variants (Richards et al., 2015; Li and Wang, 2017). The consequences of *HCNI* variants were interpreted on isoform NM\_021072.3 using Alamut 2.10 (Interactive Biosoftware, France).

### Patch-Clamp experiments

The plasmid containing the human *HCNI* cDNA differing from the *HCNI* reference sequence (NM\_021072.3) by a deletion of 3 bp encoding one of the 12 glycine residues starting from residue 63 (known polymorphism) was kindly provided by Dr. Juliane Stieber (Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany). The properties of the HCN1 channel with this in-frame variant were comparable to that of HCN1 corresponding to the reference sequence. Ten of the novel identified variants (M153I, M243R, K261E, M305L, G391C, G391D, G391S, I397L, S399P and R590Q) were introduced into this *HCNI* cDNA with the QuikChange Site-Directed Mutagenesis Kit (Stratagene). All constructs were sequenced to ensure that no additional variants were introduced. Whole-

cell patch-clamp experiments were performed at room temperature in CHO-K1 cells transiently cotransfected with 1  $\mu\text{g}$  of plasmid expressing the wild-type (WT) or a mutant human HCN1 (hHCN1) channel plus pEGFP (at a ratio of 50(pHCN1):1(pEGFP)), using the Neon<sup>TM</sup> transfection system (Invitrogen), and whole-cell patch clamp experiments were performed at room temperature 24 hours after transfection, as previously described (Nava *et al.*, 2014a). For coexpression experiments, an equal amount of WT and M153I constructs (0.5  $\mu\text{g}$  of each plasmid) was transfected in the same conditions.

The biophysical properties of M305L, G391C, G391D, G391S and I397L were further studied in HEK293T cells transiently transfected with WT and/or mutant constructs using Turbofect transfection reagent (Thermo Fisher). 1  $\mu\text{g}$  or 0.5  $\mu\text{g}$  of the *HCN1*-containing vector (pcDNA3) and 0.3  $\mu\text{g}$  of GFP-containing plasmid (pmaxGFP, AmaxaBiosystems) were transfected. In coexpression studies, 0.5  $\mu\text{g}$  each *HCN1* plasmid was cotransfected. Green-fluorescent cells were recorded by whole-cell patch-clamp at room temperature 24 hours after transfection, as previously described (Lolicato *et al.*, 2014).

Finally, the C329S and V414M variants were introduced in pIRES-GFP-hHCN1-WT (GenBank: AF488549.1). CHO cells were transiently transfected with 1.5  $\mu\text{g}$  of WT or mutant in pIRES-GFP-hHCN1 plasmid using the jetPRIME reagent (Polyplus Transfection, Euroclone). Whole-cell patch clamp experiments were performed at room temperature 48 hours after transfection, as previously described (Gravante *et al.*, 2004).

## Data Analysis

To analyse current density, the steady-state current amplitude was measured at the end of each test potential and normalized to cell capacitance. Mean activation curves were

obtained by fitting maximal tail current amplitude, plotted against the voltage step applied, with the Boltzmann equation  $I_t = I_t(\text{max}) / (1 + \exp((V - V_{1/2})/k))$  where  $I_t$  is the current amplitude of the tail current recorded for a given pre-pulse and  $I_t(\text{max})$  is the maximum current amplitude of the tail current,  $V$  is the voltage of the prepulse,  $V_{1/2}$  is the half-activation potential and  $k$  is the inverse slope factor in mV using Originpro software (Originlab, Northampton, MA, USA). All data are presented as mean  $\pm$  S.E.M.

### Molecular dynamics (MD) simulations

Residues 94 to 403 of the crystal structure of *HCNI* (PDB: 5U6P) (Lee and MacKinnon, 2017) were used as starting point of MD simulations. Missing residues were added and *in-silico* point variants were introduced using Modeller 9.19 (Fiser *et al.*, 2000), followed by protonation of titratable side chains according to their estimated pKa value (PROPKA3)(Olsson *et al.*, 2011). The proteins were embedded into an equilibrated palmitoylcholinephosphatidylcholine (POPC) bilayer consisting of 512 lipids using *g\_membed* (Wolf *et al.*, 2010).  $K^+$  ions were placed in the SF at binding site S4 and in the central cavity (Scav). Finally, the internal cavity was solvated with VOIDOO/FLOOD (Kleywegt and Jones, 1994). The resulting system consisted of the protein, 494 POPC, 41911 TIPS3P water, 126  $K^+$  and 114  $Cl^-$  ( $\approx 0.15$  mol l<sup>-1</sup>) for the heterozygous mutation, 441941 TIPS3P water, 122  $K^+$  and 114  $Cl^-$  for the WT channel and 41970 TIPS3P water, 124  $K^+$  and 114  $Cl^-$  for the heterozygous mutation, respectively. Simulations employed the GROMACS software package (2018) (Van Der Spoel *et al.*, 2005; Pronk *et al.*, 2013) and CHARMM36m forcefield (Huang and MacKerell, 2013). The integration time step was set to 2fs. Van der Waals forces were switched to zero between 0.8 and 1.2 nm.

Electrostatic interactions were represented using the fast smooth particle-mesh Ewald (PME) method with a Coulomb cut-off of 1.2 nm (Essman, 1995). Hydrogen bonds were kept constant using the LINCS algorithm (Hess, 1997). The velocity-rescale thermostat (Bussi *et al.*, 2007) with a coupling time constant of 0.1 ps was used to keep the simulation temperature at 298 K. The pressure was kept at 1 bar using the Parrinello-Rahman barostat algorithm (Parrinello, 1981) with a coupling constant of 5 ps. Prior to 100 ns production simulation, the system was energy minimized (5,000 steps steepest descend) and equilibrated (10 ns NPT simulation). During equilibration, protein heavy atoms were restrained to their initial position by a force constant of 1,000 kJ mol<sup>-1</sup> nm<sup>-2</sup>.

The raw data that support the findings of this study are available from the corresponding authors, upon request.

## Results

We collected the data of 33 affected individuals carrying 18 different novel *HCNI* missense variants classified as pathogenic or likely pathogenic using the ACMG criteria, all absent from the GnomAD database (Fig. 1, Supplementary Table 1). Overall, 14 different variants occurred *de novo* in 19 sporadic patients (Table 1). Four variants segregated with epilepsy in at least two affected family members of four families (Table 2). All 18 variants led to missense substitutions altering amino acids highly conserved in orthologs and/or paralogs (Supplementary Fig.1). Five amino acid substitutions (Met153Ile, Met243Arg, Met305Leu, Gly391Ser and Gly391Asp) were each observed twice, Met305Leu and Met153Ile resulting from different nucleotides substitutions. Three different base changes altering glycine 391 (Gly391Ser, Gly391Cys and Gly391Asp) were observed in five

patients.

The spectrum of phenotypic manifestations related to the occurrence of pathogenic and likely pathogenic *HCNI* variants is illustrated in Fig. 2A. To display results in a clear and effective way, sporadic and familial cases were analysed separately.

### Sporadic epilepsy phenotypes related to *de novo*, pathogenic *HCNI* variants

At the time of the study, the 19 probands harbouring *de novo HCNI* variants (11 females and 8 males) had a median age of 12.0 years (mean age: 13.2, ranging from 1 to 42 years). Table 1 summarizes the main clinical features of sporadic patients and additional details are provided in Supplementary Table 2. Median age at seizure onset was 7 months (mean age: 11.8 months, ranging from 30 hours to 72 months). At onset, seizure types were heterogeneous including mainly generalized episodes, triggered by febrile illness in seven patients (36.8%; patients 2, 4-7, 14, 18). Yet, only two of them were reported to have had prolonged FS and hemiclonic component in one. Six patients (31.5%; patients 1, 3, 10, 11, 16, 19) had generalized seizures including absences, eyelid myoclonia and afebrile tonic-clonic seizures (TCS). In five probands (26.3%; patients 8, 9, 12, 13, 15), initial seizures were classified as possibly focal with a variable combination of symptoms including hypotonia, hypomotor behavior, apnea and cyanosis, tonic posturing, clonic jerking with or without secondary generalization. In patient 17, characterization of the first seizure was difficult and left as unclassified.

At follow up, all 19 patients had had subsequent polymorphic seizures, either focal or generalized, occurring with variable frequency, from multiple per day (patients 1, 2, 9, 12,

13, 16-19) to weekly (patient 3) to monthly (patients 7 and 11) or rare (patients 5, 6, 8, 10, 14, 15) events. A 42 year-old patient (patient 4) has been seizure-free and off antiepileptic drugs (AEDs) for over 20 years. Patients 12 and 13 respectively deceased at 14 and 15 months, due to cardiopulmonary failure, and while living, both had a very severe and drug resistant epilepsy with dozens of daily seizures. Both patients presented worsening of seizure frequency while treated with phenytoin and lacosamide. Overall, at least 10 out of the 17 living patients (58.8%) with seizures at the time of the study, had a drug resistant epilepsy not responding to combination of several conventional AEDs. The remaining patient with FS (patient 6) is currently 2 years and 6 months old and she has seizures only during febrile illnesses.

Following the ILAE guidelines for epilepsy classification (Fisher *et al.*, 2014), three probands (15.7%; patients 4, 16, 19) were considered as having GGE including CAE with typical 3 Hz spike and waves (Fig. 2B), or GGE with TCS and epilepsy with eyelid myoclonia; 5 probands (26.3%; patients 5-7, 14, 15) were classified within the GEFS+ spectrum; 7 probands (36.8%; patients 1, 2, 11-13, 17, 18 ) had a neonatal/infantile onset otherwise unclassified EE. The remaining 4 patients (21%) had infantile onset focal (patient 9), or infantile onset unclassified epilepsy (patients 3, 9, 10).

All patients underwent periodic EEG recordings from seizure onset to current age. According to their epilepsy phenotype, EEG recordings showed either focal, multifocal or generalized paroxysmal activity. Brain MRI was normal or showed non-specific brain abnormalities including parietal, occipital or fronto-temporal atrophy (two patients), thin corpus callosum and mild diffuse white matter hyperintensity (one patient each). Patients 10-12 had acquired microcephaly (Supplementary Fig. 2). Patient 12 underwent several

video-EEG monitoring from birth up to age 14 months and numerous focal seizures with an ictal discharge shifting from one hemisphere to the other in the same event were recorded (Fig. 2C). Due to these peculiar migrating seizures, an initial diagnosis of malignant migrating partial seizures of infancy (MMPSI) was suspected, but *KCNT1* mutation was ruled out.

Motor and cognitive development were normal in six patients (31.5%; patients 3, 6-8, 14, 19) with only mild language developmental delay in two, whereas 13 probands (68.4%) had a variable degree of ID ranging from mild in four patients (21%; patients 3, 4, 10, 15), to moderate in three (15.7%; patients 5, 9, 16) and to severe ID in the remaining six (31.5%; patients 1, 11-13, 17, 18), with autistic traits in two.

#### Families with inherited, likely pathogenic *HCNI* variants

We identified *HCNI* variants segregating with epilepsy in four families (Table 2, Fig. 3A), for a total of 20 individuals (7 males and 13 females), 14 of whom exhibited an epilepsy phenotype while six were not known to have had seizures.

Family T included three siblings and their father, all exhibiting seizures and carrying the Thr171Arg variant. All individuals manifested febrile and afebrile seizures beginning in infancy and childhood with an overall benign outcome. One of the twin girls is still on valproic acid (VPA) at age 21 years and has yearly seizures; the remaining two siblings and the father have been seizure-free without taking AEDs for several years. The brother and the father had borderline cognitive function, whereas the twin sisters showed mild ID. Family M1 included five family members with epilepsy, all carrying the Cys329Ser variant. The proband and four additional symptomatic relatives spread over three

generations, exhibited infantile-onset febrile and afebrile TCS. One individual manifested also a non-progressive action myoclonus; all had normal or borderline cognitive and motor functions. Their EEG recording and MRI were unremarkable.

Family M2 included six family members carrying the Val414Met variant. The proband, her sister and their maternal uncle presented late infantile, early childhood onset febrile and febrile TCS. The remaining *HCNI* variant carriers were not known to have had seizures. All six family members had normal development and those with seizures had unremarkable MRI and EEG recordings. Only the proband is still on AEDs.

Finally, family O included five individuals carrying the Ser680Tyr variant although only two were clinically affected. The proband, a girl with normal development, presented with a first generalized TCS at age 7 years and EEG recording showed generalized photoparoxysmal response. Her mother, carrying the same variant had a history of absence seizures in childhood and was treated with VPA. The three remaining *HCNI* variant carriers were not known to have had seizures.

Thus, the milder outcome and epilepsy phenotypes, including afebrile tonic-clonic seizures and absences with predominant FS, observed in these four families were consistent with GEFS+ conditions.

#### Extended *HCNI* spectrum: variants of unknown significance (VUS)

We also collected electroclinical and genetic data of eight probands with VUS in *HCNI* (Supplementary Table 3, Supplementary Fig. 3).

A 9 year-old adopted male (patient 34) with severe EIEE had two predicted damaging variants, one missense (Lys261Glu) in domain S4, and one G>A transition abolishing the

donor splice site of intron 5 (c.1377+1G>A). We could not determine whether these variants were located on the same allele (*cis*) or on different parental alleles (*trans*) due to absence of DNA from biological parents and unavailability of patient's material.

Two patients with no history of seizures had *de novo HCN1* variants identified by WES or medical exome sequencing. Patient 35 was an 8-year-old-male with moderate intellectual disability and acquired microcephaly carrying a *de novo* nonsense mutation (Tyr138\*). Patient 36 had severe ID and language delay associated with the *de novo* Met379Arg variant in the S6 transmembrane (TM) domain.

Two sporadic female patients had intragenic deletions encompassing exon 4 (encoding the pore of the channel and segment S6), inherited in both cases from their asymptomatic father. Patient 37 had moderate ID, severe behavioural disturbances (agitation, auto- and hetero-aggressive behaviours) and ASD. Patient 38 had global developmental delay, behavioural disturbances with intolerance to frustration, and peculiar facial features (long face, arched eyebrows, marked but short philtrum, and epicanthus). This latter patient had a *HCN1* deletion extending to exon 5 and also carried a *de novo* 339kb 17q12 duplication (arr[hg19] 17q12(37332899\_37672040)) of unknown significance.

Finally, three sporadic patients (patients 39-41) with mild GGE and GEFS+ phenotypes carried *HCN1* missense variants inherited from an asymptomatic parent. Proband 39 had the Glu85Ala variant, inherited from his asymptomatic mother, and exhibited GGE with tonic-clonic seizures at age 11 years and generalized spike wave discharges enhanced during intermittent photic stimulation. He also manifested cortical tremor with giant evoked potentials and positive C-reflex. Similarly, a 15-year-old female (proband 41) carrying the Arg715Gly variant inherited from her asymptomatic father, exhibited absence

seizures with 3 Hz spike-wave discharges on EEG recordings at age 7 years leading to a diagnosis of childhood absence epilepsy. The remaining proband had infantile onset of febrile and afebrile TCS suggestive of a GEFS+ phenotype and carried the Tyr411Cys variant (proband 40), inherited from his asymptomatic father.

### Genotype-phenotype correlations

We further investigated the correlations existing between variants and their associated phenotypes. Twelve of the 14 *de novo* pathogenic missense variants clustered in TM domains of HCN1 including S1, S4, S5 and S6 segments or were located in close proximity to domains S3/S6 (Fig. 1A and 1B), whereas the four missense variants identified in families were all located outside TM segments, either in extracellular loops (S1-S2: T171R; S5-P: C329S) or in the intracellular C-terminal domain (p.V414M, S680Y). Of the two *de novo* variants located outside TM domains, one (R590Q) affected a residue of the cyclic nucleotide-binding domain (CNBD) critical for cAMP binding (Zagotta *et al.*, 2003; Lolicato *et al.*, 2011) and was associated with a mild generalized epilepsy phenotype. All four VUS identified in patients with mild phenotypes, although predicted to be damaging, were also located outside TM domains, either in the N or C-terminal regions. Altogether, these observations suggested that variants located in TM segments or domains required for formation of the pore structure are generally associated with more severe phenotypes than variants located in extracellular loops or N/C-terminal domains.

Patients with identical *de novo* variants strikingly had concordant phenotypes, indicating that the phenotype was largely determined by the mutation itself: patients 2 and 3 (M153I) both exhibited an infantile onset epilepsy, although patient 2, who was older, also had

seizures increased during febrile illness and mild ID; patients 5 and 6 (M243R) had fever-related seizures; patients 14 and 15 (G391S) both had infantile onset of febrile and afebrile seizures; patients 12 and 13 with G391D showed neonatal epileptic encephalopathy with severe, intractable seizures and profound cognitive and motor delay leading to death at ages 14 and 15 months. The only exception was Met305Leu, caused by two different base changes, in patients 10 and 11 who had apparently dissimilar phenotypes, although patient 10 was an infant whereas patient 11 was an adolescent. Yet, both patients had similar postnatal microcephaly (Supplementary Fig. 2).

#### Functional impact of inherited, likely pathogenic variants

To determine the functional impact on the biophysical properties of the channel, we performed whole-cell patch-clamp recordings in CHO cells for two of the four inherited, likely pathogenic *HCN1* variants. *HCN1* C329S exhibited a smaller current density compared with the WT channel (Fig. 3B-C), but comparable voltage-dependence of activation (Fig. 3D). The activation and deactivation kinetics were not altered (Fig. 3E). Conversely, *HCN1* V414M showed a current density similar to the WT channel (Fig. 3B-C) but the half-activation voltage ( $V_{1/2}$ ) was shifted to the right by ~5mV with faster activation kinetics at all tested voltages (Fig. 3D-E). These results suggest that these two familial variants behave as mild loss-of-function (LoF) or gain-of-function (GoF) of homotetrameric *HCN1* channels, respectively.

#### Functional impact of *de novo* pathogenic variants

We then carried out whole-cell patch-clamp recordings in CHO cells transiently transfected with WT HCN1 or mutant HCN1 channels corresponding to ten selected *de novo* HCN1 variants. No  $I_h$  current was recorded from cells transfected with M305L, G391D and S399P and rarely from cells transfected with K261E (Fig. 4A-C), indicating a probable LoF for these mutants. Recordings were inconstant in CHO cells for G391C, G391S and I397L, preventing a detailed analysis (Fig. 4E). All mutant channels leading to a LoF were expressed and reached the plasma membrane although their quantity was highly decreased for all except G391C, with the lowest amounts observed for K261E and M305L (Supplementary Fig. 4). On the contrary, voltage-dependent, slowly activating inward currents were recorded upon hyperpolarization in cells transfected with WT, M153I, M243R and R590Q channels, consistent with an expression of functional channels (Fig. 4A-B). Current densities were significantly decreased for M243R and R590Q compared to the WT channel. M153I had major effects on channel gating (Fig. 4D), as the half-activation voltage was shifted to the depolarizing direction by ~36 mV compared to WT channel. The M153I variant also resulted in significantly faster activation and slower deactivation kinetics than WT HCN1 (Fig. 4E). In contrast, the half-activation voltage of R590Q was shifted to the hyperpolarizing direction by ~9 mV, without significant effect on the activation and deactivation kinetics. To mimic the heterozygous state of the mutation, we performed coexpression of WT HCN1 and the more interesting variant, M153I. The shift of the half-activation voltage was intermediate between WT and homomeric channels, shifted to the depolarizing direction ~12 mV compared to WT channel. These results largely confirmed that both *de novo* and inherited HCN1 variants associated with epilepsy may indifferently lead to LoF or GoF of homotetrameric HCN1

channel properties in heterologous cells, without any immediately obvious correlation between phenotypes and the effects on homomeric channels.

To gain further insight into the mechanisms by which *HCNI* variants cause divergent phenotypes, M305L, G391S, G391C G391D and I397L mutant channels were expressed alone or in combination with the WT channel to study the behaviour of homo and heterotetrameric channels in human HEK293 cells, as we found that these mutants express more robustly in this cell line compared to CHO cells, allowing a more detailed characterization. (Fig. 5).

When the mutant HCN1 subunits were expressed alone, a current was recorded for M305L, G391S and G391C, and I397L but not for G391D (Fig. 5A, D, G, J and M). When the WT and mutant forms were cotransfected, all the variants gave rise to measurable currents (Fig. 5A, D, G, J and M). The amount of current recorded from G391S, G391C, I397L either alone or cotransfected with the WT, were comparable to the WT condition (Fig. 5E, H and N). Interestingly, the analysis of the voltage dependence of G391S and G391C channels (Fig. 5F and I) indicates a strong but opposite effect of the two variants on  $V_{1/2}$ . G391S induced a right shift of +21 mV (Fig. 5F), while mutation G391C led to a left shift of -19 mV (Fig. 5I). The behaviour of the heteromeric channels was intermediate in both cases, with respective shifts of +11.5 mV (G391S) and -4 mV (G391C). I397L showed the strongest shift of the  $V_{1/2}$  (+40 mV) and, similarly to G391S and G391C, the coexpression with the WT subunit conferred an intermediate phenotype with a shift of the  $V_{1/2}$  of +20mV (Fig. 5O).

Differently, the M305L substitution caused a decrease in the number of cells that were expressing current, with 45% of measured cells showing a strongly reduced current density (Fig. 5B), precluding the analysis of tail currents. Interestingly, the coexpression of mutant and WT subunits rescued this current loss, returning the current density values and the number of cells expressing current to the range of the WT condition (Fig. 5B, Supplementary Fig. 5). However, the analysis of the voltage dependence of this heteromeric channel showed a right shift of the  $V_{1/2}$  of +12mV and an increase in slope factor (Supplementary Table 4), indicating different gating properties than the WT channel (Fig. 5C).

A more severe picture emerged for the G391D mutant. On one hand, both the lack of current in the mutant and the halved current of the coexpression (roughly comparable to half dose of the WT, Fig. 5K), suggested a possible lack of expression for this subunit. On the other hand, the G391D/WT currents showed features which were clearly specific to the coexpression of WT/G391D subunits, such as the presence of an instantaneous component (Fig. 5J and K) and a strong reduction (80%) in the number of transfected cell expressing a measurable current (Fig. 5L), suggesting that the heteromeric channel can form, and, although poorly, conduct current.

### Impact of G391D on channel structure

To better understand the impact of the G391D mutation, associated with the most severe neonatal epileptic encephalopathy phenotype, on HCN1 protein structure/function, we performed MD simulations on the transmembrane domains of WT and mutant channels. The G391D variant generated an opening of the inner channel gate by ca. 1.8 Å during the

first 25 ns of simulation. This favoured an influx of water into the channel cavity, which was absent in the WT channel (Fig. 6A, Supplementary Fig. 6A-B). The presence of carboxyl groups in mutant channels caused a strong binding of potassium ions to one or multiple aspartate 391 residues (Fig. 6B). While this position was not occupied by a cation in the WT channel (Fig. 6E), the mutant remained in this open- but non-conducting conformation for the whole 100 ns of simulation (Fig. 6F). The results of these simulations are consistent with the electrophysiological data, which showed that the homomeric channels are non-conductive, presumably because the ionic path is blocked by cations firmly bound to Aspartate 391. In addition, they correspond to previous findings on HCN global dynamics (Weissgraeber *et al.*, 2017). A similar inhibition of channel conductance by an ion, which is complexed by negative charges at the entry into the cavity, was also reported previously (Tayefeh *et al.*, 2007).

We then simulated the behaviour of the heteromeric HCN1 channels in which two of the four subunits carried the G391D variant. The simulation showed that channels in which the mutation was introduced in opposite monomers behave like the homomeric mutants; water enters the cavity and  $K^+$  ions associate to Aspartate 391, blocking conductance of the channel (Fig. 6D, H). In contrast, when the mutation was introduced in adjacent subunits, the channel remained closed. There was no entry of water and no blockage by  $K^+$  ions during 100 ns of simulation (Fig. 6C, H). These results are also in agreement with the electrophysiological recordings, which showed that some functional HCN1 type currents can be measured in a few cells expressing a mixture of WT and mutant channels. It is interesting to note that the helices, which carried the mutation in adjacent monomers showed small deformations (Fig. 6C). It is therefore tempting to speculate that this small

widening of the inner gate, which is caused by the greater space requirement of the aspartate side chain, is responsible for the large instantaneous current observed for the heteromeric channels.

## Discussion

### *HCNI* spectrum

We previously described five *de novo* *HCNI* missense variants in patients with a Dravet-like phenotype (Nava *et al.*, 2014a), recognized as early infantile epileptic encephalopathy-24 (EIEE24; OMIM #615871). Since then, a single independent study has reported a *de novo* *HCNI* variant (p.Ala387Ser) in a patient with Rett-like syndrome (Lucariello *et al.*, 2016). The clinical spectrum associated with *HCNI* variants has thus remained largely unknown. The analysis of the electroclinical features of 33 patients harbouring *de novo* and inherited heterozygous *HCNI* variants uncovered a wide phenotypic spectrum ranging from mild GGE and GEFS+ phenotypes, to infantile onset focal or unclassified epilepsies to catastrophic epilepsies assembled under the term of ‘neonatal/infantile epileptic encephalopathies’. One of the two patients with neonatal onset epileptic encephalopathy carrying the G391D variant, exhibited video-EEG recorded prolonged focal seizures with an ictal discharge shifting from one hemisphere to the other within the same event, suggesting a diagnosis of MMPSI. This study also provides further evidence that there is a biological and clinical continuum between mild, benign generalized epilepsies and severe epileptic encephalopathies, as the result from genetic variants in the same gene, as previously observed for other genes encoding ion channels (*e.g.* *SCN1A*, *SCN2A* and *KCNQ2*). In our cohort, 36.8% of the sporadic and about 20% of the whole cohort exhibited severe epilepsy corresponding to EIEE whilst the great majority of both sporadic (42%) and familial cases manifested a milder phenotype comprehensive of a less severe epilepsy, associated with mild ID or normal cognition. Indeed, more than 65% of our patients manifested FS, FS+ or GGE including CAE with normal or borderline cognitive and motor

functions.

The electroclinical features of cortical tremor with photosensitivity and of non-progressive action myoclonus in two individuals with *HCNI* variants corroborates the hypothesis of neuronal hyperexcitability, possibly causing a depolarized resting membrane potential in neurons that are more prompt to firing. We speculate that this effect in the thalamocortical network similarly results in abnormal generalized spike-wave activity, a hallmark of GGE, observed in patients with *HCNI* variants. *HCNI* is also moderately expressed in the heart (source: GTEX). Yet, contrary to patients with *HCN4* pathogenic variants (DiFrancesco, 2013), no obvious cardiac abnormalities have been yet reported in patients with *HCNI* variants. This is an important aspect that should also be accounted for in further studies.

### Genotype-phenotype correlations and impact of *HCNI* pathogenic variants

Overall, *HCNI* variants causing severe phenotypes tended to cluster within or close to TM domains and have stronger impact on channel function whereas variants segregating with milder phenotypes were located in extracellular loops or in the intracellular N- and C-terminal parts of the channel and had milder effects on  $I_h$  current. Additionally, noticeable phenotypic concordance was observed in pairs of patients harbouring identical *de novo* *HCNI* variants, indicating that the epilepsy phenotype is largely determined by this single variant. In particular, G391D observed in two unrelated patients, one of Italian origin and the other Portuguese, caused an almost identical catastrophic neonatal phenotype. Both probands presented with severe, intractable epileptic encephalopathy with daily seizures

from the first days of life, and never acquired psychomotor skills. Seizure semiology was also very similar with asymmetrical tonic posturing and predominant dysautonomic signs including apnoea and cyanosis. Two patients with a different change (G391S) altering the same amino acid both showed milder phenotypes consistent with GEFS+ spectrum. The three different changes altering Glycine 391 show that the phenotype is not only determined by the position of the altered amino acid on the channel but also by the nature and consequence of the amino acid change. The impact of G391S/C, associated with milder phenotypes, was limited to shifts in the voltage dependency of the channel, whereas G391D, causing the most severe phenotype, corrupted channel function in a more complex manner: WT/mutant heteromeric channels exhibited a strong reduction in current density with a high instantaneous activating current component. MD simulation revealed that the Aspartate at the entrance to the inner pore cavity electrostatically interacts with cations preventing, in the homozygous condition, or altering, in the heterozygous state, their permeation. These results show that different amino acid substitutions at a critical position can either reduce (LoF) or increase (GoF) HCN1 homomers conductance. However, mutation spectrum and coexpression studies suggest that seizures are specific to variants leading to shifts in heteromeric channel properties that could also be interpreted as a GoF impact. We hypothesize that variants leading to a GoF lead to neuronal hyperexcitability sustaining seizures, while variants leading to haploinsufficiency of *HCN1* result, on the contrary, in neuronal hypoexcitability and predispose to ID/ASD, as previously demonstrated for *SCN2A* (Ben-Shalom *et al.*, 2017; Wolff *et al.*, 2017). More suitable neuronal and animal models are needed to fully understand the complexity of the effects resulting from *HCN1* dysfunction related to epilepsy and ID.

## Variants of unknown significance

The observation of an adopted child with severe EIEE harbouring both missense (p.Lys261Glu) and splice site variants suggested that this severe phenotype could be associated with recessive inheritance. Functional analysis of p.Lys261Glu further confirmed that it leads to a probable LoF of homomeric channels. Yet, the phase of the variants (*i.e.* location in *cis* or in *trans*) could not be determined due to the unavailability of parental and patient's material. Further evidence is therefore needed to conclude on the existence of recessive *HCN1* disorders. The contribution of variants introducing premature termination codon (including the *de novo* nonsense variant identified in this study) and of intragenic deletions (*e.g.* deletion of exon 4 described here in two patients), which are likely to lead to heterozygous LoF of the mutated allele remains unclear. The same applies to *de novo* variants associated with ID/ASD phenotypes without seizures. For this reason, we classified these variants as VUS, although they probably contribute to ID/ASD in the patients described in this study. ASD in patients with *HCN1* variants could be related to the interaction of HCN1 channels with SHANK3, a scaffolding protein highly enriched in the post-synaptic density of glutamatergic synapses, whose genetic alterations have been linked to ASD (Yi *et al.*, 2016; Zhu *et al.*, 2018). Finally, *HCN1* missense variants located in parts of the channel more tolerant to variations (*e.g.* N-/C-terminal domains) seem associated with a lower penetrance of epilepsy/ID phenotypes. Inherited *HCN1* VUS described in this study could even act as susceptibility factors and interact with variants in other genes to determine to occurrence of polygenic epilepsy, as described in the WAG/Rij rat (Wemhoner *et al.*, 2015).

In conclusion, this study provides a comprehensive delineation of the phenotypic spectrum associated with *HCN1* variants ranging from GEFS+ or GGE to neonatal or infantile EE. Recurrent variants showed striking genotype-phenotype correlations. *HCN1* pathogenic variants might be either *de novo* or dominantly inherited and lead to GoF or dominant negative effects underlying neuronal hyperexcitability in various neuron types including the thalamocortical network, thus generating aberrant generalized spike-waves as observed in our patients. Animal models reproducing *HCN1* variants should help understanding more accurately the associated pathophysiological mechanisms in the hope to develop more adapted treatments for this group of disorders.

## **Acknowledgments**

We thank the patients and their family for their participation in this study, Dr. Juliane Stieber (Universität Erlangen-Nürnberg, Germany) for providing plasmids containing the human HCN1 cDNA and Prof. Dirk Isbrandt (German Center for Neurodegenerative Diseases (DZNE) and University of Cologne) for critical reading of the manuscript and interesting discussions. Calculations required for MD simulations were conducted on the Lichtenberg high performance computer of the TU Darmstadt. The Mariani Foundation, which promoted and organised the International Workshop on the Genetic Epileptic Encephalopathies, Florence 2016, is also acknowledged. This Workshop was the starting point of an international collaboration leading to the creation of the HCN1-consortium. Data collection and generation within this fruitful international collaboration has led to this manuscript. The research leading to these results was partly generated on the

electrophysiology core facility of the institute of brain and spine (ICM, Paris). This study also makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from <http://decipher.sanger.ac.uk> and via email from [decipher@sanger.ac.uk](mailto:decipher@sanger.ac.uk). Funding for the project was provided by the Wellcome Trust.

## **Funding**

The research generating these results was funded by the Agence National de la Recherche (ANR EUHFAUTISM), the “Investissements d’avenir” program ANR-10-IAIHU-06 (IHU-A-ICM), the Bio-Psy labex, INSERM, the Assistance Publique des hôpitaux de Paris (AP-HP), the Pierre and Marie Curie University, the Italian Ministry of Health (Ricerca Finalizzata Giovani Ricercatori), projects GR-2010-2304834 to JCD and AB and GR-2016-2363337 to JCD, the Ministry of Research and the Arts (HMWK) of the Hessen state (LOEWE project iNAPO), and the Telethon Exploratory Project GEP14137 to A.M.

## **Competing interests**

S.I is employed by Ambry Genetics and FK is medical director of Mendelics Genomic Analysis, companies that provide gene panel and medical exome sequencing as commercially available tests. All other authors report no competing interests.

## **Appendix**

### **Collaborators (ULB)**

Vilain Catheline<sup>34,35,36</sup>, Bouysran Youssef<sup>35,36</sup>, Aeby Alec<sup>37</sup>

<sup>34</sup> Department of Genetics, Hôpital Universitaire des Enfants Reine Fabiola, ULB Center of Human Genetics, Université Libre de Bruxelles, Brussels, Belgium.

<sup>35</sup> Department of Genetics, Hôpital Erasme. ULB Center of Human Genetics, Université Libre de Bruxelles, Brussels, Belgium.

<sup>36</sup> Interuniversity Institute of Bioinformatics in Brussels, Université Libre de Bruxelles, Brussels, Belgium.

<sup>37</sup> Department of Pediatric Neurology. Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium.

## References

- Ben-Shalom R, Keeshen CM, Berrios KN, An JY, Sanders SJ, Bender KJ. Opposing Effects on NaV1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures. *Biol Psychiatry* 2017; 82(3): 224-32.
- Benarroch EE. HCN channels: function and clinical implications. *Neurology* 2013; 80(3): 304-10.
- Bender RA, Soleymani SV, Brewster AL, Nguyen ST, Beck H, Mathern GW, *et al.* Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus. *J Neurosci* 2003; 23(17): 6826-36.
- Biel M, Wahl-Schott C, Michalakis S, Zong X. Hyperpolarization-activated cation channels: from genes to function. *Physiol Rev* 2009; 89(3): 847-85.
- Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. *J Chem Phys* 2007; 126(1): 014101.
- Chen S, Wang J, Siegelbaum SA. Properties of hyperpolarization-activated pacemaker current defined by coassembly of HCN1 and HCN2 subunits and basal modulation by cyclic nucleotide. *J Gen Physiol* 2001; 117(5): 491-504.
- DiFrancesco D. Funny channel gene mutations associated with arrhythmias. *J Physiol* 2013; 591(17): 4117-24.
- DiFrancesco JC, DiFrancesco D. Dysfunctional HCN ion channels in neurological diseases. *Front Cell Neurosci* 2015; 6: 174.

Essman UP, L.; Berkowitz, M.L. A smooth particle mesh Ewald method. *Journal of Chemical Physics* 1995; 103: 8577–93.

Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, *et al.* DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. *Am J Hum Genet* 2009; 84(4): 524-33.

Fiser A, Do RK, Sali A. Modeling of loops in protein structures. *Protein Sci* 2000; 9(9): 1753-73.

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, *et al.* ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* 2014; 55(4): 475-82.

Gravante B, Barbuti A, Milanesi R, Zappi I, Viscomi C, DiFrancesco D. Interaction of the pacemaker channel HCN1 with filamin A. *J Biol Chem* 2004; 279(42): 43847-53.

Hess BB, H.; Berendsen, H.J.C.; Fraaije, J.G.E.M. . LINCS: A linear constraint solver for molecular simulations. *Journal of Computational Chemistry* 1997; 18: 1463–72.

Huang J, MacKerell AD, Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. *J Comput Chem* 2013; 34(25): 2135-45.

Lee CH, MacKinnon R. Structures of the Human HCN1 Hyperpolarization-Activated Channel. *Cell* 2017; 168(1-2): 111-20 e11.

Li Q, Wang K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. *Am J Hum Genet* 2017; 100(2): 267-80.

Lolicato M, Bucchi A, Arrigoni C, Zucca S, Nardini M, Schroeder I, *et al.* Cyclic dinucleotides bind the C-linker of HCN4 to control channel cAMP responsiveness. *Nat Chem Biol* 2014; 10(6): 457-62.

Lolicato M, Nardini M, Gazzarrini S, Moller S, Bertinetti D, Herberg FW, *et al.*  
Tetramerization dynamics of C-terminal domain underlies isoform-specific cAMP gating  
in hyperpolarization-activated cyclic nucleotide-gated channels. *J Biol Chem* 2011;  
286(52): 44811-20.

Lucariello M, Vidal E, Vidal S, Saez M, Roa L, Huertas D, *et al.* Whole exome  
sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical  
phenotype. *Hum Genet* 2016; 135(12): 1343-54.

Ludwig A, Zong X, Jeglitsch M, Hofmann F, Biel M. A family of hyperpolarization-  
activated mammalian cation channels. *Nature* 1998; 393(6685): 587-91.

Monteggia LM, Eisch AJ, Tang MD, Kaczmarek LK, Nestler EJ. Cloning and localization  
of the hyperpolarization-activated cyclic nucleotide-gated channel family in rat brain.  
*Brain Res Mol Brain Res* 2000; 81(1-2): 129-39.

Moosmang S, Biel M, Hofmann F, Ludwig A. Differential distribution of four  
hyperpolarization-activated cation channels in mouse brain. *Biol Chem* 1999; 380(7-8):  
975-80.

Nava C, Dalle C, Rastetter A, Striano P, de Kovel CG, Nabbout R, *et al.* De novo  
mutations in HCN1 cause early infantile epileptic encephalopathy. *Nat Genet* 2014a;  
46(6): 640-5.

Nava C, Keren B, Mignot C, Rastetter A, Chantot-Bastarud S, Faudet A, *et al.*  
Prospective diagnostic analysis of copy number variants using SNP microarrays in  
individuals with autism spectrum disorders. *Eur J Hum Genet* 2014b; 22(1): 71-8.

Noam Y, Bernard C, Baram TZ. Towards an integrated view of HCN channel role in  
epilepsy. *Curr Opin Neurobiol* 2011; 21(6): 873-9.

Olsson MH, Sondergaard CR, Rostkowski M, Jensen JH. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. *J Chem Theory Comput* 2011; 7(2): 525-37.

Parrinello MR, A. Polymorphic transitions in single crystals: A new molecular dynamics method. *Journal of Applied Physics* 1981; 52: 7182-90.

Parrini E, Marini C, Mei D, Galuppi A, Cellini E, Pucatti D, *et al.* Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes. *Hum Mutat* 2017; 38(2): 216-25.

Poolos NP. Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Ion Channelopathy in Epilepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. *Jasper's Basic Mechanisms of the Epilepsies*. 4th ed. Bethesda (MD); 2012.

Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. *Nat Neurosci* 2002; 5(8): 767-74.

Postea O, Biel M. Exploring HCN channels as novel drug targets. *Nat Rev Drug Discov* 2011; 10(12): 903-14.

Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, *et al.* GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. *Bioinformatics* 2013; 29(7): 845-54.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; 17(5): 405-24.

Santoro B, Liu DT, Yao H, Bartsch D, Kandel ER, Siegelbaum SA, *et al.* Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. *Cell* 1998; 93(5): 717-29.

Tayefeh S, Kloss T, Thiel G, Hertel B, Moroni A, Kast SM. Molecular dynamics simulation of the cytosolic mouth in Kcv-type potassium channels. *Biochemistry* 2007; 46(16): 4826-39.

Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. *J Comput Chem* 2005; 26(16): 1701-18.

Weissgraeber S, Saponaro A, Thiel G, Hamacher K. A reduced mechanical model for cAMP-modulated gating in HCN channels. *Sci Rep* 2017; 7: 40168.

Wemhoner K, Kanyshkova T, Silbernagel N, Fernandez-Orth J, Bittner S, Kiper AK, *et al.* An N-terminal deletion variant of HCN1 in the epileptic WAG/Rij strain modulates HCN current densities. *Front Mol Neurosci* 2015; 8: 63.

Wolf MG, Hoefling M, Aponte-Santamaria C, Grubmuller H, Groenhof G. *g\_membed*: Efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation. *J Comput Chem* 2010; 31(11): 2169-74.


Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E, *et al.* Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. *Brain* 2017; 140(5): 1316-36.

Yi F, Danko T, Botelho SC, Patzke C, Pak C, Wernig M, *et al.* Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. *Science* 2016; 352(6286): aaf2669.

Zagotta WN, Olivier NB, Black KD, Young EC, Olson R, Gouaux E. Structural basis for modulation and agonist specificity of HCN pacemaker channels. *Nature* 2003; 425(6954): 200-5.

Zhu M, Idikuda VK, Wang J, Wei F, Kumar V, Shah N, *et al.* Shank3-deficient thalamocortical neurons show HCN channelopathy and alterations in intrinsic electrical properties. *J Physiol* 2018.


# FIGURE LEGENDS



**Figure 1 Schematic representation of *HCNI* variants on the gene and protein.**

(A). Location of variants identified in this study (above) or previously reported (Nava et al. 2014; below) on schematic representations of the *HCNI* coding exons (NM\_021072.3)

and corresponding protein domains. Variants in black correspond to *de novo* variants identified in EIEE or GGE patients. Variants in blue are dominantly inherited within GGE-GEFS+ families. Variants in orange are of unknown significance. Variants indicated with a star are present in an adopted individuals with severe EIEE. **(B)** Location of *HCN1* variants on a schematic representation of the HCN1 channel. **(C)** Comparison of the variants identified in patients with neurodevelopmental phenotypes (above) and variants present in ExAC (below), showing that in control populations, variants clustered in N- and C-terminal regions of the HCN1 protein, which are more tolerant to genetic variation while pathogenic variants tend to cluster to functional or transmembrane domains of the channel.




**Figure 2 Clinical spectrum associated with *HCN1* variants and examples of EEG recordings in *HCN1* patients**

(A). Graphic representation of the phenotypic spectrum associated with *HCNI* variants.

(B) EEG recorded in patient 19 the *HCNI* p.Arg590Gln variant, showing typical, generalized 3Hz spike wave discharges lasting 10 seconds recorded while the patient was having an absence seizure.








(C) Ictal EEG recordings of patient 12, carrying the p.Gly391Asp mutation, at age 3 months, showing a focal migrating seizure lasting 18 minutes; seizure starts with a focal paroxysmal ictal discharge (PA) over the left hemisphere (6 minutes) then the PA migrates to the right hemisphere for additional 12 minutes. Seizure semiology showed: motor arrest, loss of contact, mild tachycardia, and polypnea with severe cyanosis and intermittent tonic posturing with vibratory jerking either on the right or the left arm and leg depending upon ictal discharge being to the right or the left hemisphere. This figure shows representative fragments of this seizure: PA over the left hemisphere at onset (1<sup>st</sup> panel); outbreak of ictal independent yet concomitant PA over the right posterior region (P4-02 and T6-02 leads, 2<sup>nd</sup> panel); shift of the PA from the left to the right (3<sup>rd</sup> panel); right sided PA (4<sup>th</sup> panel).



**Figure 3 Pedigrees of families with dominantly inherited *HCN1* variants and functional impact of variants identified in families M1 and M2.**


(A) Pedigrees of families T, M1, M2 and O. m/+ denotes the presence of a heterozygous mutation; +/+ denotes the absence of mutation on both alleles. The patient numbers are indicated for affected individuals and refer to numbering in Table 2. (B) Representative current traces recorded from CHO cells transfected with plasmid expressing human HCN1 WT, HCN1 p.Cys329Ser (C329S), or HCN1 p.Val414Met (V414M). From a holding

potential of -30 mV, hyperpolarizing steps in the range of -35 to -125 mV followed by a step at -125 mV were applied to measure activation curves in standard two-step protocols. (C) Current density (pA/pF) curve as a function of test voltage for HCN1-WT (empty circles), C329S (filled green circles) and V414M (filled blue squares). (D) Activation curves are presented as normalized tail current obtained for HCN1-WT (empty circles), C329S (filled green circles) and V414M (filled blue squares). (E) Mean activation (left) and deactivation (right), time constant ( $\tau$ ) curves obtained for HCN1-WT (empty circles), C329S (filled green circles) and V414M (filled blue squares). Data are presented as means  $\pm$  S.E.M. with the numbers of experiments for each condition indicated in parentheses. Statistical analysis was performed by one-way ANOVA with a significance level set to  $*P < 0.01$ . Values for half activation potential ( $V_{1/2}$ ) and inverse slope factor ( $k$ ) are reported in Supplementary Table 4.




**Figure 4 Functional impact of selected *de novo* HCN1 variants using whole-cell patch-clamp.**

(A) Representative traces of whole-cell currents recorded in CHO cells transfected with constructs for wild-type (WT), M153I, M243R, M305L, G391D, S399P or R590Q human HCN1 channels. Currents were elicited by test pulses ranging from -20 mV to -130 mV in 10mV increments from a holding potential of -20mV. (B) Plot of mean current density as a function of test voltage for WT, M153I, M243R, K261E, M305L, G391D, S399P and R590Q human HCN1 channels (two-way ANOVA, \*P < 0.05). (C) Mean tail current activation curves for WT, M153I, M243R, and R590Q HCN1 channels. (D) M153I mutant channels have faster activation time constants than WT HCN1 channel (two-way ANOVA, \*P < 0.05). The M153I mutant channels also display significantly increased deactivation time constants compared with those of WT HCN1 (one-way ANOVA, \*\*P < 0.01 for voltage -60mV). (E) Plot of the percent of cells expressing the  $I_h$  current for all variants (F) Mean tail current activation curves for WT, M153I and WT/M153I HCN1 channels. (G) Plot of the percent of cells expressing the  $I_h$  current for all variants tested. Data are presented as means  $\pm$  S.E.M. with the numbers of experiments for each condition indicated in parentheses. Values for half activation potential ( $V_{1/2}$ ) and inverse slope factor ( $k$ ) are reported in Supplementary Table 4.



**Figure 5 Functional impact of variants altering Glycine 391, Isoleucine 397 and Methionine 305 on HCN1 homotetramers and heterotetramers.**

Representative current traces recorded by whole-cell patch-clamp using the indicated voltage step protocol from HEK293 cells transiently transfected with 1 $\mu$ g of plasmid DNA of HCN1 WT, M305L (**A**), G391S (**D**), G391C (**G**), G391D (**J**), and I397L (**M**) channels, as indicated. Mean steady state current/voltage relationship (I/V) from cells transfected with WT channel (closed black circles); WT/M305L and M305L (open and closed violet circles) (**B**), WT/G391S and G391S (open and closed blue circles) (**E**), WT/G391C and G391C (open and closed red circles) (**H**), WT/G391D and G391D (open and closed orange circles) (**K**) or WT/I397L and I397L (open and closed green circles) (**N**). Mean activation curves of WT, M305L (**C**), G391S (**F**), G391C (**I**) and I397L (**O**) channels, both in homo- and heterotetrameric conditions. Lines show data fit to a Boltzmann function yielding half activation potential ( $V_{1/2}$ ) and inverse slope factor ( $k$ ) values reported in Supplementary Table 4. (**L**) Histogram showing the percentage of cells expressing current of WT (100%), G391D (0%) and WT/G391D (25%). The percentage of expression for all others variants are shown in supplementary Fig. 5. All values are reported as mean  $\pm$  SEM.



**Figure 6. MD simulation of the effect of G391D on HCN1 channel structure.**

Results of MD simulations of HCN1 WT and G391D mutant channel in POPC membrane:

(A) Overlay of snapshots from S6 domains in bottom view perspective from the cytosol towards channel cavity for WT (grey) and homozygous G391D mutant (teal-blue) after a total simulation time of 25 ns. (B) Snap shot of homozygous mutant with K<sup>+</sup> ion (sphere) complexed by Asp391 (orange). (C) Snap shot of heterozygous mutant with Asp391 in two adjacent monomers without bound K<sup>+</sup> ion. (D) Snap shot of heterozygous mutant with Asp391 in two opposite monomers with bound K<sup>+</sup> ion. Lower row shows trajectories of potassium ions along the channel axis of HCN1 in WT channel (E), homozygous G391D mutant (F), heterozygous mutant with G391D in two adjacent monomers (G), and heterozygous mutant with G391D in two opposite monomers (H). The K<sup>+</sup> binding site S4 in the selectivity filter is located at 0 nm while residue 391 is at ~ - 1.5 nm. For clarity, only a subset of all ions is shown.

Patient number	Gender	age at the study	Sz onset	Sz type at onset	Sz type at follow-up	Sensitivity to fever	Sz frequency	Resistance to AEDs	Development	Epilepsy type/syndromes	mutation
1	F	12 y 6 m	12 m	TCS	TCS, At	N	D	Y	Severe ID	EIEE	p.Phe143Tyr
2	F	7 y 3 m	5 m	FS	Fc, TCS	Y	W to D	Y	Mild ID	EIEE	p.Met153Ile
3	M	2 y 8 m	9 m	TCS	TCS, Fc	N	W	Y	Mild language delay	Uncl Epi infantile onset	p.Met153Ile
4	F	42 y	7 m	FS	FS, afebrile TC, Tn & Ab	Y	last sz @ 20y	N	Mild ID + autistic traits	GGE-TCS	p.Thr172Pro
5	F	17 y	13 m	FS	FS, afebrile TCS, Ab	Y	R	N	Moderate ID	FS+	p.Met243Arg
6	F	2 y 6 m	10 m	FS (Tn)	FS	Y	w fever	N	Normal	FS	p.Met243Arg
7	F	2 y	8 m	FS (Cl)	Cl Gen	Y	Mt	N	Normal	FS+	p.Thr260Ile
8	M	5 y 10 m	9 m	Fc (Cl)	TCS	N	R	N	Normal, mild language delay	Uncl Epi infantile onset	p. Ser264Cys
9	F	9 y	42 m	Fc	Fc > TCS; My	N	D	Y	Moderate ID	Childhood Focal Epi	p.Ile275Thr
10	F	12 m	3 m	TCS	TCS	N	4 m sz-free	N	Mild DD	Uncl Epi infantile onset	p.Met305Leu
11	F	14 y	2 m	TCS	TCS, Tn, Fc, Cl	Y	Mt	Y	Severe ID, microcephaly	EIEE	p.Met305Leu
12	M	died at 14 m	30 h	Tn asymmetric, prolonged	Tn asymmetric +/- Cl, prolonged apnea & cyanosis	N	D	Y	Severe ID, microcephaly	NOEE (MMPSI)	p.Gly391Asp
13	M	died at 15 m	48 h	Tn asymmetric, prolonged	Similar but w cyanosis	N	D	Y	Severe ID	NOEE	p.Gly391Asp
14	F	6 y 3 m	5 m	Prolonged FS (20')	FS; afebrile TCS: Fc (LOC, hypotonia, cyanosis, vomit)	Y	Yr	N	Normal	FS+	p.Gly391Ser
15	M	2 y 5 m	7 m	HemiCl	Fc, TCS	Y	Yr	N	Mild ID	GEFS+	p.Gly391Ser

<b>16</b>	F	29 y	Infancy	Eyelid My	TCS, Fc, Ab, My	NA	Mt to W	Y	Moderate ID, autistic traits	Gen Epi w eyelid My	p.Gly391Cys
<b>17</b>	M	15 y	5 m	Hypotonia and cyanosis few h after vaccination	MA; Fc (hypomotor w psychomotor arrest) TCS	Y	D	Y	Severe ID, autistic traits	EIEE	p.Ile397Leu
<b>18</b>	M	7 y	4 m	Prolonged FS	TCS, w apnea	Y	D	Y	Severe ID	EIEE	p.Ser399Pro
<b>19</b>	M	15 y	72 m	Ab	Ab + single TCS	N	D	Y	Normal	CAE	p.Arg590Gln

**Table 1 Clinical and genetic summary of the 19 sporadic patients with *de novo* *HCNI* variants.**

F: female; M: male; h: hours; m: months; y: years; Ab: Absence; At: atonic; Cl: clonic; Fc: focal; Gen: generalized; My: myoclonic; Epi: Epilepsy; FS: febrile seizures; MA: myoclonic-atonic; TCS: tonic-clonic seizure(s); Tn: tonic; Uncl: unclassified; Sz: seizure(s); Y: Yes; N: No; @: at; w: with; D: daily; W: weekly; Mt: Monthly; Yr: Yearly; DD: developmental delay; ID: intellectual disability; LOC: Loss of consciousness; CAE: childhood absence epilepsy; EIEE: early infantile epileptic encephalopathy; FS+ febrile seizure plus; GGE: genetic generalized epilepsy; GEFS+: generalized epilepsy with febrile seizure plus; NOEE: neonatal-onset epileptic encephalopathy; NA: unavailable. Detailed clinical information, including Brain MRI, EEG findings and antiepileptic treatment is displayed for patients 1-19 in Supplementary Table 2.

Family	Patient number	Gender	Age at study	Seizure onset	Seizure type	sz at follow-up	AEDs	EEG	Brain MRI	Development	Epilepsy type/syndromes	Mutation
Family T	20	M	66 y	8 m	FS & afebrile TCS	sz until age 6 y then single TCS in adult age	PB, currently no AEDs	Normal	NA	NA	GEFS+	p.Thr171Arg
	21	M	32 y	8 m	FS; TCS, Possible Focal onset >TCS	sz-free from age 12 y	PB + GVG +VPA currently no AEDs	Normal	Normal	Borderline	GEFS+	
	22	F	21 y	10 m	FS	FS & afebrile TCS, sz-free for > 3 y	VPA, ESM, currently no AEDs	GSW	Normal	Mild ID (TIQ=50)	GEFS+	
	23	F	21 y	11 m	FS	FS & afebrile TCS, sz-free for from 10 to 18 y	VPA	Normal	Normal	Mild ID (TIQ=66)	GEFS+	
Family M1	24	F	49 y	3 m	FS, febrile, afebrile TCS	sz-free from age 12 y after CBZ	CBZ	NA	NA	Normal	GEFS+	p.Cys329Ser
	25	F	29 y	1 y	FS	sz-free after VPA	VPA	NA	NA	Normal	FS	
	26	F	6 y	18 m	TCS wo fever	Status epilepticus episode treated by PHT then sz-free on VPA	VPA	Normal	Normal	Normal	GGE	

	27	M	23 y	8 m	Febrile TCS	FS & afebrile sz and ab from age 4 y; non progressive action myoclonus from age 8 y; sz-free after VPA	VPA	Normal	Normal	Mild ID (TIQ=52; VIQ=46; PIQ=70)	GGE	
	28	F	20 y	13 m	FS	sz-free w CBZ until 13 y; CBZ was suspended: sz recurrence. sz-free following CBZ reintroduction	CBZ	Normal	Normal CT scan	Normal	GEFS+	
Family M2	29	F	8 y	18 m	FS, febrile and afebrile TCS	sz-free after VPA	VPA	Fast activity	Normal	Borderline (WIPPSI: IQ=77)	GEFS+	p.Val414Met
	30	F	5 y	18 m	FS	sz-free	no AEDs	Rare focal PA, fast activity	Normal	Borderline (DQ Griffith scale=70)	GEFS+	
	31	M	59 y	12 m	FS	sz-free	no AEDs	NA	NA	Normal	FS	
Family O	32	F	7 y	7 y	TCS	sz-free	VPA	GSW during IPS	Normal	Normal	GGE	p.Ser680Tyr
	33	F	Unknown	Childhood	Ab	ab & single TCS in	no AEDs	GSW	Normal	Normal	CAE	

						childhood, then sz-free						
--	--	--	--	--	--	----------------------------	--	--	--	--	--	--

**Table 2 Clinical and genetic summary of affected members of families with *HCNI* variants.** F: female; M: male; m: months; y: years; Ab: Absence; FS: febrile seizure plus; TCS: tonic-clonic seizure(s); Sz: seizure(s); Antiepileptic drugs (AEDs): CBZ: carbamazepine, ESM: ethosuximide, GVG: Vigabatrin, PB: phenobarbital, VPA: sodium valproate; GSW: generalized spike and wave; IPS: intermittent photic stimulation; GGE: genetic generalized epilepsy; GEFS+: generalized epilepsy with febrile seizure plus; ID: intellectual disability; DQ: developmental quotient; IQ: intellectual quotient; PIQ: performance intellectual quotient; TIQ: full-scale intellectual quotient; VIQ: verbal intellectual quotient; NA: unavailable.

## Supplementary material



### ***HCN1* mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond**

Carla Marini<sup>1,43,\*#</sup>, Alessandro Porro<sup>2\*</sup>, Agnès Rastetter<sup>3\*</sup>, Carine Dalle<sup>3\*</sup>, Iliaria Rivolta<sup>4</sup>, Daniel Bauer<sup>5</sup>, Renske Oegema<sup>6</sup>, Caroline Nava<sup>3,7,43</sup>, Elena Parrini<sup>1</sup>, Davide Mei<sup>1</sup>, Catherine Mercer<sup>8</sup>, Radhika Dhamija<sup>9</sup>, Chelsea Chambers<sup>10</sup>, Christine Coubes<sup>11</sup>, Julien Thévenon<sup>12</sup>, Paul Kuentz<sup>12,13</sup>, Sophie Julia<sup>14</sup>, Laurent Pasquier<sup>15</sup>, Christèle Dubourg<sup>16</sup>, Wilfrid Carré<sup>16</sup>, Anna Rosati<sup>1</sup>, Federico Melani<sup>1</sup>, Tiziana Pisano<sup>1</sup>, Maria Giardino<sup>1</sup>, A. Michel Innes<sup>17</sup>, Yves Alembik<sup>18</sup>, Sophie Scheidecker<sup>18</sup>, Manuela Santos<sup>19</sup>, Sonia Figueiroa<sup>19</sup>, Cristina Garrido<sup>19</sup>, Carlo Fusco<sup>20</sup>, Daniele Frattini<sup>20</sup>, Carlotta Spagnoli<sup>20</sup>, Anna Binda<sup>4</sup>, Tiziana Granata<sup>21</sup>, Francesca Ragona<sup>21</sup>, Elena Freri<sup>21</sup>, Silvana Franceschetti<sup>21</sup>, Laura Canafoglia<sup>21</sup>, Barbara Castellotti<sup>21</sup>, Cinzia Gellera<sup>21</sup>, Raffaella Milanesi<sup>22</sup>, Maria Margherita Mancardi<sup>23</sup>, Damien R. Clark<sup>24</sup>, Fernando Kok<sup>25</sup>, Katherine L. Helbig<sup>26</sup>, Shoji Ichikawa<sup>27</sup>, Laurie Sadler<sup>28</sup>, Jana Neupauerová<sup>29</sup>, Petra Laššuthova<sup>29</sup>, Katalin Štěrbová<sup>29,43</sup>, Annick Laridon<sup>30</sup>, Eva Brilstra<sup>6,43</sup>, Bobby Koeleman<sup>6,43</sup>, Johannes R. Lemke<sup>31,43</sup>, Federico Zara<sup>32</sup>, Pasquale Striano<sup>33,43</sup>, Soblet Julie<sup>34,35,36</sup>, Smits Guillaume<sup>34,35,36</sup>, Deconinck Nicolas<sup>37</sup>, Andrea Barbuti<sup>22</sup>, Dario DiFrancesco<sup>22</sup>, Eric LeGuern<sup>3,7,43</sup>, Renzo Guerrini<sup>1,43</sup>, Bina Santoro<sup>38</sup>, Kay Hamacher<sup>5</sup>, Gerhard Thiel<sup>39</sup>, Anna Moroni<sup>2</sup>, Jacopo C. DiFrancesco<sup>21,40</sup>, Christel Depienne<sup>3,41,42,43#</sup>


#### **AFFILIATIONS**

<sup>1</sup> Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Neuroscience Department, A. Meyer Children's Hospital, University of Florence, Viale Pieraccini 24, 50139, Florence, Italy. <sup>2</sup> Department of Biosciences, University of Milan, 20133 Milan, Italy. <sup>3</sup> Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France. <sup>4</sup> School of Medicine and Surgery, University Milano-Bicocca, Monza, Italy. <sup>5</sup> Computational Biology & Simulation Group, Department of Biology, Technische Universität Darmstadt, 64287 Darmstadt, Germany. <sup>6</sup> Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. <sup>7</sup> AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique, 75013, Paris, France. <sup>8</sup> Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK. <sup>9</sup> Department of Clinical Genomics and Neurology, Mayo Clinic, Phoenix, AZ, USA. <sup>10</sup> Department of Neurosciences, University of Virginia, Charlottesville, VA, 22908, USA. <sup>11</sup> Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, Montpellier, France. <sup>12</sup> FHU-TRANSLAD, Université de Bourgogne/CHU Dijon and INSERM UMR 1231 GAD team, Genetics of Developmental Anomalies, Université de Bourgogne-Franche Comté, Dijon, France. <sup>13</sup> Génétique Biologique Histologie, CHRU de Besançon, Besançon, France. <sup>14</sup> Service de génétique médicale, Pôle de biologie, CHU de Toulouse - Hôpital Purpan, Toulouse, France. <sup>15</sup> Service de Génétique Clinique, Centre Référence « Déficiences Intellectuelles de causes rares » (CRDI), CHU Rennes, 35203 Rennes, France. <sup>16</sup> Laboratoire de Génétique Moléculaire & Génomique, CHU de Rennes, 35033 Rennes, France. <sup>17</sup> Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. <sup>18</sup> Laboratoires de génétique, Institut de génétique médicale d'Alsace, Hôpitaux Universitaires de Strasbourg, 67 000 Strasbourg, France. <sup>19</sup> Neuropediatric Department, Centro Hospitalar do Porto, Porto Portugal. <sup>20</sup> Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy. <sup>21</sup> Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. <sup>22</sup> Department of Biosciences, The PaceLab, Università degli Studi di Milano, Milan, Italy. <sup>23</sup> Child Neuropsychiatry Unit, Department of Medical and Surgical Neurosciences and Rehabilitation, IRCCS Istituto Giannina Gaslini, Genova, Italy. <sup>24</sup> Women's and Children's Hospital, Adelaide, Australia. <sup>25</sup> Mendelics Genomic Analysis, Sao Paulo, SP, Brazil. <sup>26</sup> Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. <sup>27</sup> Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, CA, USA. <sup>28</sup> Division of Genetics, Department of Pediatrics, Oishei Children's Hospital, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, State University of New York, Buffalo, NY, 14203, USA. <sup>29</sup> Department of Child Neurology, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. <sup>30</sup> Department of Neurology, Academic Center for Epileptology, Kempenhaeghe/Maastricht University Medical Center, Heeze, The Netherlands. <sup>31</sup> Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany. <sup>32</sup> Laboratory of Neurogenetics and Neuroscience, Institute G. Gaslini, Genova, Italy. <sup>33</sup> Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, "G. Gaslini" Institute, Genova, Italy. <sup>34</sup> Department of Genetics, Hôpital Universitaire des Enfants Reine Fabiola, ULB Center of Human Genetics, Université Libre de Bruxelles, Brussels, Belgium. <sup>35</sup> Department of Genetics, Hôpital Erasme, ULB Center of Human Genetics, Université Libre de Bruxelles, Brussels, Belgium. <sup>36</sup> Interuniversity Institute of Bioinformatics in Brussels, Université Libre de Bruxelles, Brussels, Belgium. <sup>37</sup> Department of Pediatric Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, ULB, Brussels, Belgium. <sup>38</sup> Department of Neuroscience, Columbia University, New York, NY 10032, USA. <sup>39</sup> Membrane Biophysics, Department of Biology, Technische Universität Darmstadt, 64287 Darmstadt, Germany. <sup>40</sup> Department of Neurology, San Gerardo Hospital, University Milano-Bicocca, Monza, Italy. <sup>41</sup> IGBMC, CNRS UMR 7104/INSERM U964/Université de Strasbourg, 67400 Illkirch, France. <sup>42</sup> Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany. <sup>43</sup> EuroEPINOMICS RES consortium. \* Co-first authors; #to whom correspondence should be addressed: [christel.depienne@uni-due.de](mailto:christel.depienne@uni-due.de) or [carla.marini@meyer.it](mailto:carla.marini@meyer.it)







**Supplementary Figure 2. Head circumference charts of patients with M305L.** Growth charts of patients 11 (A) and 10 (B) with the M305L variants showing similar trajectories of head circumference with low-normal measurement at birth and progressive decrease during the first year of life, resulting in postnatal microcephaly.




**Supplementary Fig. 3 Pedigrees of families with variants of unclear significance in *HCNI*.**



**Supplementary Fig. 4 Expression of HCN1 variants in CHO-transfected cells.** Western blot analysis of HCN1 protein expression in whole lysates (A) and plasma membrane fraction (B) of CHO transfected cells expressing WT or mutant HCN1 channels. Actin and flotillin were used to control and normalise the protein load. Note that the fraction of protein at the plasma membrane is, to some extent, related to cell survival after transfection: WT: 70%; p.Lys261Glu: 40%; p.Met305Leu: 30%; p.Gly391Ser: 15%; p.Gly391Cys: 70%; p.Gly391Asp: 40%; p.Ile397Leu: 50%; c.1195T>C; p.Ser399Pro: 40%).



**Supplementary Fig. 5.** Histogram showing the percentage of cells expressing  $I_h$  current for *HCN1* pathogenic variants expressed in HEK293 cells corresponding to results presented in Figure 5.



**Supplementary Fig. 6. Effect of G391D mutation on structure and function correlates in HCN1 channel.** (A) Snap shots of cavity in HCN1 WT channel (left) and homozygous G391D mutant (right) in side view perspective after 25 ns of simulation. Note that the number of water molecules (red spheres) in the cavity is higher in mutant than in wt. (B) Number of water molecules in the cavity of HCN1 channel over time of simulation for WT channel (upper left), homozygous G391D mutant (upper right), and heterozygous mutant with Asp391 in opposite monomers (lower left) or in adjacent monomers (lower right).

Patient number	34	35	36	37	38	39	40	41
Gender	F	M	F	F	F	M	M	F
Age at study	9 y 5 m	8 y	6 y	21 y	20 y	17 y	7 y	15 y
Seizure onset	7 m	–	–	–	–	11 y	14 m	84 m
Seizure type	Focal (hypomotor)	–	–	–	–	TCS during sleep	FS	Absence
Seizures at follow-up	Atonic, focal dyscognitive, atonic	–	–	–	–	TCS > sleep	FS, TCS, Ab	Absence daily
Seizure frequency	Daily	–	–	–	–	Yearly	sz free	daily Absence
AEDs	LTG, OXC, RFN, CLB, Leucovorin, LEV, KD	–	–	–	–	VPA, LEV, VPA, VPA+CLN	–	ESM, CLN, LEV, LTG
EEG	Bursts of GSW, often lateralized to either hemisphere, electrographic seizures in the posterior hemisphere	–	Normal Abundant beta waves rythm	Ininterpretable (artifacted EEG due to behavioral disturbances)	Normal	GSW, positive IPS with GSW from 12 to 30 Hz stimulation	Multifocal PA > sleep	GSW
Brain MRI	Cortical and white matter volume loss in the parietal and occipital lobes	Normal	Normal	Normal	Normal	Normal	Normal	Normal
Development	Severe ID, wheel chair bound, cannot walk, no meaningful words, hypotonia, no consistent visual tracking	Developmental delay: sitting at 13m; walking at 27m; 1st words at 3y; currently moderate ID; acquired microcephaly (-1SD)	Psychomotor delay currently severe ID, few isolated words	Developmental delay, severe behavioral disturbances (agitation, isolation, temper tantrums, auto- and hetero-agressivity), moderate ID	Developmental delay, behavioural disturbances (intolerance to frustration), moderate ID	Normal	Normal	Borderline
Epilepsy type/syndrome	EIEE	ID no epilepsy	ID no epilepsy	ID/ASD no epilepsy	ID no epilepsy	GGE-TCS	GEFS+	CAE

Mutation	p.Lys261Glu; c.1377+1G>A	p.Tyr138*	p.Met379Arg	exon 4 deletion	exon 4 deletion	p.Glu85Ala	Tyr411Cys	Arg715Gly
Inheritance	Unknown	<i>de novo</i>	<i>de novo</i>	Inherited from unaffected father	Inherited from unaffected father	Inherited from unaffected mother	Inherited from unaffected father	Inherited from unaffected father
family history	patient adopted	no	no	no	no	no	yes	Yes

**Supplementary Table 3 Clinical and genetic summary of the 9 patients with variants of unclear significance in *HCNI*.** CAE: childhood absence epilepsy; EIEE: early infantile epileptic encephalopathy; FS: febrile seizures; FS+ febrile seizure plus; GGE: genetic generalized epilepsy; GEFS+: generalized epilepsy with febrile seizure plus; TCS: tonic-clonic seizure; ID: intellectual disability; ASD: autism spectrum disorders. Antiepileptic drugs (AEDs): CLB: clobazam, CLN: clonazepam, KD: ketogenic diet, LCM: lacosamide, LEV: levetiracetam, LTG: lamotrigine, OXC: oxcarbamazepine, RFN: rufinamide, VPA: sodium valproate.

Condition	$V_{1/2}$ (mV)	$k$ (mV)
Figure 3		
HCN1 WT	$-79.4 \pm 0.4$	$7.3 \pm 0.3$
HCN1 p.C329S	$-79.3 \pm 0.3$	$7.8 \pm 0.3$
HCN1 p.V414M	$-74.7 \pm 0.3$	$7.2 \pm 0.3$
Figure 4C		
HCN1 WT	$-70.1 \pm 1.0$	$13.5 \pm 0.7$
HCN1 p.M153I	$-34.0 \pm 0.6$	$13.2 \pm 0.4$
HCN1 p.M243R	$-68.0 \pm 1.3$	$20.8 \pm 1.1$
HCN1 p.R590Q	$-79.1 \pm 1.86$	$10.4 \pm 1.2$
Figure 4F		
HCN1 WT	$-64.3 \pm 1.2$	$15.1 \pm 0.9$
HCN1 p.M153I	$-34.4 \pm 1.7$	$20.2 \pm 1.5$
HCN1 WT/HCN1 p.M153I	$-52.3 \pm 0.9$	$16.4 \pm 0.5$
Figure 5		
HCN1 WT	$-72.6 \pm 0.7$	$6.4 \pm 0.5$
HCN1 p.WT/M305L	$-60.9 \pm 1.9$	$11.4 \pm 0.6$
HCN1 WT (panel B)	$-72.9 \pm 0.7$	$6.9 \pm 0.6$
HCN1 p.G391S	$-51.5 \pm 0.9$	$8.1 \pm 0.4$
HCN1 p.WT/G391S	$-61.5 \pm 0.6$	$11.2 \pm 0.8$
HCN1 WT (panel E)	$-71.5 \pm 1$	$5.4 \pm 0.2$
HCN1 p.G391C	$-90.6 \pm 1.2$	$12.2 \pm 1.3$
HCN1 p.WT/G319C	$-74.2 \pm 2$	$15.4 \pm 1.3$
HCN1 WT	$-72.2 \pm 0.9$	$7.2 \pm 0.4$
HCN1 p.I397L	$-32.9 \pm 1.7$	$10.3 \pm 0.3$
HCN1 p.WT/I397L	$-54.2 \pm 2.2$	$9.4 \pm 0.8$

**Supplementary Table 4. Midpoint of activation and relative voltage sensitivity of HCN1 wild-type and mutant channels.** Half-activation voltage ( $V_{1/2}$ ) and slope factor ( $k$ ) obtained by fitting a Boltzmann function, corresponding to whole-cell patch-clamp experiments presented in Figures 3, 4 and 5, are shown.